Literature DB >> 15821750

Neuroprotective activity of the mGluR5 antagonists MPEP and MTEP against acute excitotoxicity differs and does not reflect actions at mGluR5 receptors.

Paul M Lea1, Vilen A Movsesyan, Alan I Faden.   

Abstract

1 Neuroprotection has been reported after either activation or blockade of the group I metabotropic glutamate receptor subtype 5 (mGluR5). However, some recent evidence suggests that protection provided by mGluR5 antagonists may reflect their ability to inhibit N-methyl-D-aspartate (NMDA) receptor activity. 2 Here, in both rat and mouse cortical neurons, we compare the neuroprotective actions of two mGluR5 antagonists: 2-methyl-6-(phenylethynyl)-pyridine (MPEP), which has been commonly used and 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP), a more recently developed compound believed to have greater mGluR5 selectivity. We have previously shown that MPEP directly reduces single-channel NMDA receptor open time at the same concentrations (20 microM or greater) that show neuroprotection, whereas MPEP antagonizes mGluR5 agonist ((RS)-2-chloro-5-hydroxyphenylglycine (CHPG))-induced changes in inositol phosphates (IP) at concentrations as low as 0.2 microM. 3 In the present studies, MTEP significantly inhibited CHPG-mediated IP hydrolysis at concentrations as low as 0.02 microM. In contrast to MPEP, which significantly reduced glutamate- or NMDA-mediated cell death in primary rat neuronal cultures at a concentration of 20 microM, small neuroprotective effects were observed with MTEP only at a concentration of 200 microM. Neither MPEP- nor MTEP-mediated mGluR5 inhibition had any effect on etoposide-induced apoptotic cell death. In rat cortical neurons, the neuroprotective effects of MTEP at very high concentrations, like those of MPEP, reflect ability to directly reduce NMDA receptor peak and steady-state currents. 4 We also compared the effects of MPEP and MTEP in primary cortical neuronal cultures from parental and mGluR5 knockout mice. Both agents were neuroprotective, at high concentrations in normal as well as in the knockout cultures. In contrast to rat cortical neurons, neither MPEP nor MTEP appears to directly alter NMDA receptor activity. 5 Combined, these studies support the conclusion that MTEP has greater mGluR5 selectivity than MPEP, and that neuroprotection provided by either antagonist in neuronal cultures does not reflect inhibition of mGluR5 receptors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15821750      PMCID: PMC1576169          DOI: 10.1038/sj.bjp.0706219

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  36 in total

1.  [3H]-methoxymethyl-MTEP and [3H]-methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor.

Authors:  Nicholas D P Cosford; Jeffrey Roppe; Lida Tehrani; Edwin J Schweiger; T Jon Seiders; Ashok Chaudary; Sara Rao; Mark A Varney
Journal:  Bioorg Med Chem Lett       Date:  2003-02-10       Impact factor: 2.823

Review 2.  Pharmacology and functions of metabotropic glutamate receptors.

Authors:  P J Conn; J P Pin
Journal:  Annu Rev Pharmacol Toxicol       Date:  1997       Impact factor: 13.820

3.  Activation of metabotropic glutamate receptor subtype mGluR1 contributes to post-traumatic neuronal injury.

Authors:  A Mukhin; L Fan; A I Faden
Journal:  J Neurosci       Date:  1996-10-01       Impact factor: 6.167

Review 4.  Modulation of metabotropic glutamate receptors as potential treatment for acute and chronic neurodegenerative disorders.

Authors:  Paul M Lea; Alan I Faden
Journal:  Drug News Perspect       Date:  2003-10

5.  Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands.

Authors:  M J Berridge; C P Downes; M R Hanley
Journal:  Biochem J       Date:  1982-09-15       Impact factor: 3.857

6.  In vivo receptor occupancy of mGlu5 receptor antagonists using the novel radioligand [3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine).

Authors:  Jeffery J Anderson; Margaret J Bradbury; Darlene R Giracello; Deborah F Chapman; Greg Holtz; Jeffrey Roppe; Chris King; Nicholas D P Cosford; Mark A Varney
Journal:  Eur J Pharmacol       Date:  2003-07-18       Impact factor: 4.432

7.  Activation of metabotropic glutamate receptors coupled to inositol phospholipid hydrolysis amplifies NMDA-induced neuronal degeneration in cultured cortical cells.

Authors:  V Bruno; A Copani; T Knöpfel; R Kuhn; G Casabona; P Dell'Albani; D F Condorelli; F Nicoletti
Journal:  Neuropharmacology       Date:  1995-08       Impact factor: 5.250

8.  Antagonists for group I mGluRs attenuate excitotoxic neuronal death in cortical cultures.

Authors:  U Strasser; D Lobner; M M Behrens; L M Canzoniero; D W Choi
Journal:  Eur J Neurosci       Date:  1998-09       Impact factor: 3.386

9.  Oxidative stress aspects of the cytotoxicity of carbamide peroxide: in vitro studies.

Authors:  M C Sinensky; A L Leiser; H Babich
Journal:  Toxicol Lett       Date:  1995-01       Impact factor: 4.372

10.  Activation of metabotropic glutamate receptors protects cultured neurons against apoptosis induced by beta-amyloid peptide.

Authors:  A Copani; V Bruno; G Battaglia; G Leanza; R Pellitteri; A Russo; S Stanzani; F Nicoletti
Journal:  Mol Pharmacol       Date:  1995-05       Impact factor: 4.436

View more
  27 in total

1.  Metabotropic glutamate receptor-mediated signaling in neuroglia.

Authors:  David J Loane; Bogdan A Stoica; Alan I Faden
Journal:  Wiley Interdiscip Rev Membr Transp Signal       Date:  2012-01-11

2.  Selective mGluR1 antagonist EMQMCM inhibits the kainate-induced excitotoxicity in primary neuronal cultures and in the rat hippocampus.

Authors:  Maria Śmiałowska; Krystyna Gołembiowska; Małgorzata Kajta; Barbara Zięba; Anna Dziubina; Helena Domin
Journal:  Neurotox Res       Date:  2011-12-06       Impact factor: 3.911

3.  Elevated glycogen synthase kinase-3 activity in Fragile X mice: key metabolic regulator with evidence for treatment potential.

Authors:  Wenzhong William Min; Christopher J Yuskaitis; Qijiang Yan; Christopher Sikorski; Shengqiang Chen; Richard S Jope; Robert P Bauchwitz
Journal:  Neuropharmacology       Date:  2008-10-14       Impact factor: 5.250

4.  Developing neuroprotective strategies for treatment of HIV-associated neurocognitive dysfunction.

Authors:  Jeffrey A Rumbaugh; Joseph Steiner; Ned Sacktor; Avindra Nath
Journal:  Futur HIV Ther       Date:  2008

5.  Activation of mGluR5 Attenuates Microglial Activation and Neuronal Apoptosis in Early Brain Injury After Experimental Subarachnoid Hemorrhage in Rats.

Authors:  Zong-Yong Zhang; Bao-Liang Sun; Jun-Ke Liu; Ming-Feng Yang; Da-Wei Li; Jie Fang; Shuai Zhang; Qi-Lin Yuan; Si-Luo Huang
Journal:  Neurochem Res       Date:  2015-04-07       Impact factor: 3.996

6.  Metabotropic glutamate receptor 5 activation inhibits microglial associated inflammation and neurotoxicity.

Authors:  Kimberly R Byrnes; Bogdan Stoica; David J Loane; Angela Riccio; Margaret I Davis; Alan I Faden
Journal:  Glia       Date:  2009-04-01       Impact factor: 7.452

Review 7.  Fragile X Syndrome and Alzheimer's Disease: Another story about APP and beta-amyloid.

Authors:  J S Malter; B C Ray; P R Westmark; C J Westmark
Journal:  Curr Alzheimer Res       Date:  2010-05       Impact factor: 3.498

Review 8.  Metabotropic glutamate receptor 5 - a promising target in drug development and neuroimaging.

Authors:  Rajapillai L I Pillai; Dnyanesh N Tipre
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-07       Impact factor: 9.236

9.  Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice.

Authors:  Femke M S de Vrij; Josien Levenga; Herma C van der Linde; Sebastiaan K Koekkoek; Chris I De Zeeuw; David L Nelson; Ben A Oostra; Rob Willemsen
Journal:  Neurobiol Dis       Date:  2008-04-25       Impact factor: 5.996

10.  Attenuation of cocaine self-administration in squirrel monkeys following repeated administration of the mGluR5 antagonist MPEP: comparison with dizocilpine.

Authors:  Donna M Platt; James K Rowlett; Roger D Spealman
Journal:  Psychopharmacology (Berl)       Date:  2008-05-29       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.